Trial intelligence / Profile preview

Phase III open-label study of AS03B-adjuvanted H1N1 vaccine prime-boost immunization in children and adolescents

2009-015011-41Phase 3Completed

Sponsor
GSK
Start
Sep 2009
Modality
Vaccines & Immunotherapeutics
Countries
1
01

Overview

Phase 3, open-label, single-arm trial of Q-Pan H1N1 in influenza A virus infection (H1N1), sponsored by GSK. Primary endpoint: Humoral immune response after two primary administrations. Started Sep 2009; status: completed.

02

Drugs

Q-Pan H1N1
03

Conditions

influenza A virus infection (H1N1)

Beyond the preview

Go deeper on 2009-015011-41.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2009-015011-41.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call